T roponin is the biomarker of choice for the detection of cardiac injury. To use it properly, one must understand how sensitive the specific assay being used is for detecting cardiac injury, the fact that elevated troponin levels are highly specific for cardiac injury and some critical issues related to the basic science of the protein and its measurement. In this article, we review the biology of troponin, characteristics of assays that measure serum troponin levels and how to apply these measurements to patients who present with possible cardiovascular disease. We also discuss other clinical situations in which troponin levels may be elevated.
The biology of troponin
The 3-unit troponin complex (troponin I, T and C) along with tropomyosin is located on the actin filament and is essential for the calcium-mediated regulation of skeletal and cardiac muscle contraction. 1 There are tissue-specific isoforms of troponin I, T and C. 2, 3 Because the cardiac isoform of troponin C is shared by slow-twitch skeletal muscles, troponin C does not have cardiac specificity and thus is not used in assays for the diagnosis of cardiac injury. 4 There is one cardiac troponin I (cTnI) isoform in myocardial tissue. 5 This isoform has a post-translational tail of 32 amino acids on the N-terminus. 6, 7 This sequence and the 42% and 45% dissimilarity with sequences of the other isoforms 8 have made possible the generation of highly specific monoclonal antibodies without cross-reactivity with other noncardiac forms. 9 Three genes control cardiac troponin T (cTnT). 10 These genes and alternative mRNA splicing produce a series of isoforms 10, 11 with variable sequences close to the regions of the N-terminus and C-terminus. 10, 12 Human cardiac muscle contains 4 troponin T isoforms, but only one is characteristic of the normal adult heart. 13, 14 Highly specific antibodies have been made to the N-terminus-specific sequence of this cTnT isoform. 15 The skeletal isoforms present in the fetal heart are replaced by cTnI and cTnT late during fetal development. 16, 17 cTnI is not expressed in skeletal muscle or other tissues during development 17 or in response to degenerative or regenerative muscle disease processes. 18 Thus, it is unlikely to be reexpressed in damaged tissues. The situation is more complex for cTnT. Re-expression of fetal forms occurs in cardiac tissue 12 and in diseased skeletal muscle. 19 With the firstgeneration cTnT assay, this problem was compounded by a nonspecific tag antibody that cross-reacted with troponin T in skeletal muscle. 20 Once this antibody was replaced by one with high specificity, false-positive elevations from skeletal muscle were eliminated. 15 Studies using immunohistochemistry and polymerase chain reaction have confirmed that these fetal isoforms are not detected by the assay used today. 21, 22 Thus, the assay used to measure cTnT levels has cardiac specificity equivalent to that of assays for cTnI.
Characteristics of troponin assays
Most troponin is found in the 3-unit complex (troponin I, T and C) of the contractile apparatus in myofibrils. There is also what has been termed a "cytosolic pool" of unbound troponin that is released acutely, 23, 24 mimicking the appearance kinetics of other cytosolic proteins such as creatine kinase (CK). This pool represents about 6% of cTnT 23 and 3% of cTnI, 24 which is similar to the concentration of the CK-MB isoenzyme. 24 The 13-15-fold increased amount of troponin per gram of myocardium is mostly complexed, 23, 24 which explains the late but not early release of troponin. Thus, the increased overall amount of troponin in the heart is not why troponin is more sensitive than CK-MB. 25, 26 The increased early sensitivity likely reflects the fact that the percentage of Review It has been known for 50 years that transaminase activity increases in patients with acute myocardial infarction. With the development of creatine kinase (CK), biomarkers of cardiac injury began to take a major role in the diagnosis and management of patients with acute cardiovascular disease. In 2000 the European Society of Cardiology and the American College of Cardiology recognized the pivotal role of biomarkers and made elevations in their levels the "cornerstone" of diagnosis of acute myocardial infarction. At that time, they also acknowledged that cardiac troponin I and T had supplanted CK-MB as the analytes of choice for diagnosis. In this review, we discuss the science underlying the use of troponin biomarkers, how to interpret troponin values properly and how to apply these measurements to patients who present with possible cardiovascular disease.
troponin released that reaches the blood after cardiac injury is greater for troponin than for CK-MB. 27, 28 Elevated troponin levels then persist in the blood owing to the slow release and degradation of the structural pool, 23, 29 since the half-life of troponin and its complex is about 2 hours. 30 The prolonged window during which troponin levels are elevated allows for increased clinical detection of cardiac events and thus, functionally, greater clinical sensitivity.
With the first-generation troponin assays, about 33% of patients presenting with symptoms of acute coronary syndromes were found to have elevated troponin levels in the absence of elevated CK-MB levels. 31 As assays have become more sensitive, an even greater number of patients have been identified with elevated troponin levels. Although the degree of improvement depends on the troponin assay used, the cut-off values adopted and the assay's sensitivity for CK-MB, the use of troponin rather than CK-MB has clearly increased the ability to detect myocardial damage secondary to ischemia perhaps as much as 130%. 32 However, there is huge variability in the sensitivity of assays, which is in no way reflected in the values reported for the various assays. The appropriate cut-off value for each assay is unique and cannot be compared with any other. 33, 34 These differences are due in part to the heterogeneity of the antibodies and matrix components of the assays. 9, 35 They are also due to the fact that there are various fragments of troponin that circulate, and the antibodies used in the various assays detect these fragments differently. 36 Troponin assays are not only more sensitive but are also more specific than CK-MB assays. Expression of CK-MB is not unique to the heart. 37 CK-MB is found in skeletal muscle and the gastrointestinal tract as well as in the uterus of pregnant women. 38 Moreover, in patients with myopathies, the CK-MB content of skeletal muscle can increase markedly to up to 50% of the total amount per gram of tissue. 39 In addition, CK-MB complexes with immunoglobulins can form. 40, 41 Thus, elevated CK-MB levels can occur because of analytical problems, macrocomplexes, trauma, rhabdomyolysis, myopathies or renal failure (owing to a myopathy), or during the peripartum period. 42, 43 The specificity of CK-MB can be enhanced by the calculation of the CK-MB/CK ratio. However, the use of this ratio markedly reduces sensitivity in patients with concurrent cardiac and skeletal muscle injury. 44, 45 For all intents and purposes, cTnI and cTnT provide comparable information, except in patients with renal failure (see "Troponin and renal failure").
The International Federation of Clinical Chemistry and Laboratory Medicine published quality specifications for cardiac troponin assays. 36 The values that are used to characterize a troponin assay are presented in Box 1. 46 The wide range in the ability of various assays to detect low levels of troponin is highlighted by the range in the different cut-off values (the lower limit of detection, the 99th percentile, the 10% coefficient of variation and the receiver operating characteristic [ROC] curve) ( Table 1 ). This table may be used by clinicians to correlate troponin values obtained at hospitals using different assays from their own. The sensitivity of the different cut-off values in detecting acute myocardial infarction is illustrated in Fig. 1 .
Role of troponin in acute myocardial infarction
In 2000 a joint committee of the European Society of Cardiology and the American College of Cardiology (ESC/ACC) issued new criteria that acknowledged that elevations in biomarkers were fundamental to the diagnosis of acute myocardial infarction, 47, 48 because symptoms may be atypical or nonexistent and electrocardiogram changes may be absent or nonspecific. 49 By this time, cardiac troponin had supplanted MB-CK as the biomarker of choice for the detection of cardiac injury. 50 The ESC/ACC criteria are included in Box 2.
To avoid false-positive results, the 99th percentile should be used as the cut-off value for diagnosing acute myocardial infarction. The use of 2 cut-off values 51,52 -one to define infarction and a second designation for unstable angina with some degree of myocardial necrosis -has been suggested. 51, 52 The ESC/ACC joint committee felt that this approach lacked a scientific basis. 50 Given the multiplicity of assays and the fact that different assays and laboratories advocate different cut-off values, the use of 2 cut-off values would have markedly increased the heterogeneity of diagnoses. In addition, with assays becoming more sensitive, the category of patients with unstable angina and myocardial necrosis would have increased in number. In addition, patients with elevated troponin levels have short-and long-term risk profiles, anatomy and pathophysiology similar to those of patients with conventionally diagnosed non-Q-wave myocardial infarction; therefore, singling this group out arbitrarily made little sense to the committee. 50 The 99th percentile as a cut-off value can be applied con- • Lower limit of detection: The lowest level detectable that differs from zero. Assays with a lower limit of detection are more sensitive.
• Upper limit of normal: Usually defined as the 95th percentile (mean ± 2 standard deviations) in a presumably normal "reference" population. For troponin, the European Society of Cardiology / American College of Cardiology task force recommended that the 99th percentile (mean ± approximately 3 standard deviations) be used as the cut-off point, above which any value should be considered abnormal.
• Coefficient of variation (CV): A measure of how consistently an assay is able to produce the same result on the same sample. A CV of 10% is the level of precision suggested for troponin assays.
• Receiver operating characteristic (ROC) curve: The value at which the sensitivity of the troponin level is equivalent to that of the CK-MB level.
sistently across assays even if the assays change. For some assays, but not others, there may be a need to alter the 99th percentile based on the patient's age, sex or race. [53] [54] [55] The 99th percentile should be measurable with an imprecision (coefficient of variation) of 10% or less. In July 2004 the first assay met these criteria. 56 We and others have advocated using the value at which there is 10% coefficient of variation, to avoid analytical false-positive results. 57 Like CK-MB, cardiac troponin concentrations begin to rise 4-6 hours after the onset of symptoms. Thus, a blood sample should be obtained on admission and again 6-9 hours later. Peak values occur at 18-24 hours after symptom onset. If it is difficult to ascertain the onset of symptoms, sampling should be based on the time of presentation. Values should be available within 60 minutes. 47, 48 Troponin elevations reflect myocardial damage but do not indicate its mechanism. In the absence of clinical evidence that the injury is due to coronary ischemia, other causes for cardiac damage should be sought.
If cardiac troponin assays are not available, the best alternative is CK-MB measurement (preferably CK-MB mass). As with the troponin assays, the 99th percentile should also be used as the cut-off value. Measurement of analytes such as myoglobin and CK isoforms was suggested only if the test results would result in a change in therapy. With the improvement of troponin assays, it has become less clear that these analytes play any role 58 (Fig. 1) . Previous studies that suggested they were of benefit were often based on high assay cut-off values or insensitive assays. 59, 60 Prognostic value of troponin in acute coronary syndromes Prognosis and diagnosis are different, and thus troponin elevations may in some situations help to make a diagnosis but may not be prognostic. The reason for this may be that inadequate studies have been done or that the effect is too small to detect, if it exists at all. Nonetheless, in almost all series, even minor elevations in troponin levels presage short-and longterm events. 50 However, for patients with acute coronary syndromes and, increasingly, other entities such as heart failure and pulmonary embolism, diagnostic elevations of troponin invariably have prognostic and therapeutic significance. In patients with acute coronary syndromes, elevated levels of cTnI or cTnT are an adverse prognostic indicator (Fig. 2) , even after adjustment for clinical predictors and electrocardiogram findings. 61, 62 These effects are short and long term. 31, 63 In patients with non-ST-segment elevation myocardial infarction (non-STEMI), angiographic data suggest that there are more acute and more complex plaques, more extensive disease, more thrombi and reduced Thrombolysis in Myocardial Infarction (TIMI) flow grades when troponin levels are elevated. 64, 65 The increased coagulation observed probably represents more severe disease rather than any other association. Since more severe disease may benefit from newer and more aggressive interventions, troponin elevations identify a group of patients who will benefit from therapy with delteparin and enoxaparin, studies of which showed a reduction in both mortality and recurrent 71 and randomized studies 72, 73 have confirmed that early coronary intervention also attenuates the adverse prognostic impact of troponin elevations. 74, 75 Of the agents used to treat acute coronary syndromes, only clopidogrel seems to benefit patients with and without troponin elevations. 76 Although there are no direct data, this is likely also true for ASA. Elevated troponin levels on admission are also of value for patients with ST-segment elevation myocardial infarction (STEMI). Regardless of therapy, an elevated troponin level is an independent predictor of death at 30 days and during long-term follow-up. 77, 78 This is because elevations predict incomplete epicardial and more severely impaired myocardial perfusion despite normal epicardial flow. 79 Some of this effect may be attenuated by stenting.
With both STEMI and non-STEMI, there is relation between the extent of the increase in troponin levels and adverse events. 61, 77 The prognostic value of cTnT and of cTnI appear equivalent. 80, 81 Can troponin detect reversible cardiac injury?
The question of whether biomarkers in general, or troponin in particular, are released after reversible or irreversible injury has been debated for years. 82 In animal experiments, increased CK activity in blood has been associated with evidence of irreversible cardiac injury (cell disruption). 83 Troponin elevations have not been detected in humans who experienced reversible ischemia after exercise stress testing. 84 The molecular weights of cTnI and cTnT are 23 500 and 33 500 Daltons respectively. However, even if free troponin chains are smaller than CK-MB (86 000 Daltons), much of the troponin is released as a complex with a higher molecular weight. 85, 86 Some have argued that the transient troponin release in experimental models of vital exhaustion, 87 experimental studies with longer ischemia times 88 and in some exercise studies 89,90 may be due to the release of troponin from the "cytosolic pool" only. This also has been observed in patients with pulmonary embolism 91, 92 and sepsis. 93 The failure of continuing release has been attributed to the lack of release of structurally bound troponin and thus "reversible injury." 91, 92 Such speculation fits with the known difficulty of causing right ventricular infarction 94 and with the recovery of left ventricular function in patients with septic shock. 95, 96 Since one cannot distinguish one type of release from the other, and given that the situation for troponin is likely the same for all biomarkers, it is unclear how important this issue is clinically. 50
Chest pain in the emergency department
Patients who present with chest pain, in whom unstable coronary disease is possible but not overt, are at higher risk of cardiac events if troponin is elevated. In a landmark study, Hamm and colleagues 97 evaluated the effectiveness of rapid triage using bedside tests to detect cTnI and cTnT in 733 patients with acute chest pain in an emergency department as long as one sample was obtained at least 6 hours after the onset of symptoms. Patients with normal troponin values had a negligible incidence of events over a 30-day follow-up. 97 The assays used in that study were less sensitive than contemporary assays. In another study involving patients who presented with chest pain but who had normal ECGs, coronary artery disease was found in 90% of those with an elevated troponin level and in 23% of those with a normal troponin level (p < 0.001). 98 Had the 99th percentile been used instead of the much higher ROC cut-off value for the troponin levels, even more patients with coronary artery disease would likely have been identified. When using low cut-off values for patients with a low pretest probability of disease, it is important to understand that analytical false-positive results may occur owing to imprecision of the assays at low levels. 46 
Troponin and the detection of myocardial reinfarction
Reinfarction is difficult to detect with any biomarker while values are rising or falling. Troponin is no different. However, a recent study 99 compared the patterns of increases in cTnI and CK-MB levels in 3 patients with acute myocardial infarction who had a reinfarction in hospital. In each case, substantial reelevations in cTnI levels occurred (Fig. 3) . These findings are similar to previous data, 100,101 which suggests that changes in troponin levels are adequate to diagnose reinfarction and that CK-MB measurement is not needed in this situation.
Troponin and infarct size
Infarct size can be estimated from the troponin value measured at 72 hours. The data are stronger for this approach with cTnT than with cTnI, 102,103 which suggest that the cTnT level measured at 72 hours is a good estimate of scintigraphic infarct size whether patients were reperfused or not. 103 For cTnI, peak levels work better, 28, 104 but the data vary depending on whether or not there has been acute reperfusion. 104 The estimates of infarct size are superior to those provided by CK or CK-MB.
Troponin after percutaneous coronary interventions
After percutaneous coronary interventions (PCIs), increases in troponin levels above the 99th percentile are indicative of cardiac cell injury and thus fulfill the definition of acute myocardial infarction. 47, 48 This may be a situation in which diagnosis and prognosis are different. Thus, the ESC/ACC group recommended that these cases of acute myocardial infarction be considered separately from spontaneous infarctions, that they be reported separately in clinical trials and that they have different reimbursement codes. 47, 48 The mechanisms by which PCIs cause cardiac damage are poorly defined despite the adverse consequences. 105, 106 Thus, whether minor troponin elevations have similar prognostic influence is unclear. It may depend on the cause of the elevation. Some degree of cardiac injury may be necessary to accomplish an adequate procedure, and in that situation a minor amount of cardiac injury may not be adverse. 107, 108 In other cases, elevated troponin levels may reflect more severe or diffuse disease.
Several considerations are important in regard to elevated troponin levels after PCI.
• Patients with acute coronary syndromes may have elevated troponin levels at baseline that increase owing to the continuing release of troponin rather than the release after PCI-related cardiac injury. It is known that elevated levels at baseline have prognostic importance. 77, 79 Some have suggested that increases of more than 25% should be considered due to the procedure, 58 but such increases could still be part of the initial insult with rising troponin values. This may be a group of patients in which post-PCI infarction cannot be diagnosed in the absence of clear-cut complications. A baseline troponin level is essential for the proper interpretation of post-PCI elevations. 109, 110 • Troponin measurement every 6-8 hours for 24 hours is ideal. 111 • Only one troponin assay should be used given the heterogeneity of assays. This is particularly important for multicentre trials.
• Values above the 99th percentile should be used to define elevations.
• Long-term follow-up (2-3 years) may well be helpful to define the prognostic effects of elevations. 112 None of the studies present in the literature has dealt with all of these issues. The same criteria should be used to investigate the relation between specific therapies (e.g., statins 113 ) and the prevention of myocardial damage after PCI. platelets, complement and cytokines); direct trauma to the heart; coronary artery or venous graft embolism; and other complications of the procedure. 114 Some damage is unavoidable. The relevant clinical issue is to define whether the degree of myocardial damage is "clinically significant." 114 Biomarkers cannot determine the mechanism of injury. 57 However, irrespective of the mechanism, the higher the value after surgery, the greater the damage 115, 116 and the worse the prognosis. 117, 118 Some have suggested that late-peaking elevations are indicative of graft occlusion, 119 but proof of this concept is unavailable. Eventually, the ability to monitor cardiac biomarkers should be a useful way to improve strategies for myocardial protection 120,121 and surgical approaches. 122, 123 
Troponin after cardiac surgery

Troponin and renal failure
Troponin is the biomarker of choice for detecting cardiac injury in patients with renal failure, including those with endstage renal disease (ESRD) receiving long-term dialysis. 124, 125 Among 7033 patients with suspected coronary syndromes enrolled in the Global Use of Strategies to Open Occluded Coronary Arteries IV (GUSTO-IV) trial for whom complete baseline data on cTnT levels and creatinine clearance rates were available, elevated TnT levels were found to predict shortterm prognosis regardless of creatinine clearance. 126 This correlation is probably also true for cTnI.
However, the concept that increases could be "artifactual" 109,110 remains, because asymptomatic ESRD patients are more apt to have elevated levels of cTnT than of cTnI despite the fact that the newer cTnT assays do not detect cross-reacting isoforms from skeletal muscle. 15, 21 Numerous studies have confirmed the importance of cardiovascular diseases in ESRD patients. 127, 128 Atherosclerotic risk factors such as diabetes, 129,130 hypercholesterolemia, 131,132 left ventricular hypertrophy 133, 134 and severe coronary artery calcification 135 are associated with increases in cTnT levels in hemodialysis patients, which supports the concept that elevations are secondary to myocardial injury. 136, 137 In a study by Ooi and colleagues, 138 minor elevations in troponin levels were invariably associated with pathological evidence of myocardial damage in patients with and without renal failure. Furthermore, prognostic studies have confirmed that such elevations are indicators of future cardiac events. Apple and colleagues 139 evaluated survival among 773 ESRD patients. Those with elevated cTnT levels (defined by the 99th percentile cut-off value) had an increased risk of death after 1, 2 and 3 years of follow-up. Increases in cTnT and cTnI levels in ESRD patients showed a 2-to 5-fold increase in mortality, with greater numbers of patients having an increased cTnT. These data have been confirmed in subsequent studies. Some have suggested that C-reactive protein elevations augment the prognostic significance of troponin elevations in this setting. 140, 141 Most studies have shown that only minor changes in troponin levels occur with dialysis. There are differences between cTnI and cTnI concentrations before and after dialysis: cTnI decreases or does not change, whereas cTnT concentrations increase after dialysis, albeit minimally. CK-MB can also be elevated in these patients in the absence of cardiac disease and its measurement is not helpful in these patients. 109 The critical clinical question is how to distinguish between troponin elevations that are due to acute coronary syndromes and those that are due to more chronic conditions. One way is to obtain a baseline value for comparison. The FDA has approved cTnT measurement for risk stratification and for this purpose. One can also use changing values to define acute episodes. If there are dynamic changes, acute disease is likely present. In the absence of a changing pattern, one may need to address the more chronic problem rather than treat emergently.
There is no definitive information about the diagnostic etiologies or the therapeutic and preventive strategies appropriate for dialysis patients with elevated troponin levels. 142 These elevations could reflect silent myocardial necrosis, 127 especially in patients with a history of ischemic heart disease; 132, 136 left ventricular hypertrophy associated with perfusion defects or abnormal coronary vasomotion; 136,143 left ventricular systolic dysfunction; 134 increased cardiac preload with myocardial stretch; 129,144 microvascular disease, especially in diabetic patients; 127,129 endothelial dysfunction secondary to oxidative stress and inflammation; 145,146 episodes of hypotension during dialysis; 147 or cardiac injury secondary to calcium and oxalate deposition. 148 Troponin elevations are unlikely owing to delayed clearance of troponin despite recent claims. 149 
Other clinical situations in which troponin levels may be elevated
The increased sensitivity and specificity of troponin assays now make it clear how often some degree of cardiac damage occurs. In critically ill patients, such elevations have profound prognostic importance. 150, 151 Elevations can be due to occult coronary artery or toxic substances such as tumour necrosis factor and heat-shock protein, as occurs in sepsis. 93 Elevations can also be due to either acute or more chronic processes (Box 3).
Direct damage could be secondary to physical energy of different types: mechanical (i.e., contusion, as in cardiac trauma or cardiac surgery) or electrical (e.g., cardioversion, ablation or implantable cardioverter defibrillator [ICD] firings).
• Cardiac trauma: Blunt cardiac trauma ("cardiac contusion") includes a broad spectrum of nonpenetrating trauma to the chest. CK-MB elevations are common and can come from injury to skeletal muscle. Troponin elevations are highly specific and usually indicate cardiac trauma. 45, 152 Elevations are usually modest; more extreme elevations may be due to concomitant coronary artery disease or coronary trauma. It is unclear whether troponin elevations can be used to predict complications or guide therapy. 153, 154 • Cardioversion, ablation and cardiac arrest: Elective electrical cardioversion in most patients does not result in troponin elevations. 155, 156 When present, elevations are mild. 157, 158 Elevations are more common in patients with cardiac arrest who have undergone direct-current shock (often multiple) or prolonged resuscitation, or both. 159, 160 Substantial elevations should suggest the presence of myocardial injury from causes (ischemic or not ischemic) unrelated to resuscitation. 157 Elevations after ablations are related to the amount of energy used but are usually modest. 161, 162 This is also the case for ICD firings and endomyocardial biopsies. There also could be a variety of toxic insults that may exacerbate underlying ischemic heart disease or could function to damage the heart directly.
• Sepsis: Troponin elevations in patients with sepsis are common. 163, 164 The mechanism in any given patient is unclear. Elevations could be due to underlying coronary artery disease, hypotension, septic microemboli, high doses of vasoactive drugs, or the effects of cytokines such as heatshock protein and tumour necrosis factor-α. 165 Clinically, elevations occur more frequently in patients with more severe left ventricular systolic dysfunction 163,164 and higher critical illness scores. 164, 166 Most studies found a relation between increased troponin levels and mortality. 167, 168 • Chemotherapy: Cardiotoxicity is a common complication of high-dose chemotherapy. Troponin elevations, soon after chemotherapy and in the short-term follow-up period, are associated with left ventricular dysfunction and cardiac events. 169 • Other toxins: Snake venom and other agents (e.g., catecholamines) either ingested, infused or released systemically can cause troponin elevations.
• Cardiac rhabdomyolysis: Increases in troponin levels can identify cardiac involvement with rhabdomyolysis. 170 Such elevations are associated with an adverse prognosis. 171 Damage could be secondary to inflammation (i.e., myocarditis or acute rejection) or an infiltrative process that involves the myocardium (i.e., pericarditis).
• Myocarditis: Lymphocytic infiltration of the heart, be it focal or diffuse, can easily explain troponin elevations. 172 Acutely, myocarditis can mimic acute myocardial infarction. Chronically, elevations are time-dependent 173,174 and generally occur early after the onset of symptoms. Myocarditis might also be the reason for troponin elevations after vaccination in some patients, and after systemic inflammatory illnesses such as Kawasaki disease.
• Pericarditis: In acute pericarditis, troponin elevations are common, especially when ST-segment elevation is present. 175, 176 Troponin release probably represents inflammatory involvement of the epicardium. 176 • Amyloidosis: Troponin elevations occur often in patients with amyloid infiltration of the myocardium 177 and likely in patients with other infiltrative myopathies as well. The extent of cardiac involvement in patients with primary systemic amyloidosis is the most important predictor of clinical outcome. 178 Troponin can be measured along with NTproBNP (N-terminal pro-brain natriuretic peptide) and other clinical variables for risk stratification. 179, 180 Cardiac damage can be ischemic but not be due to overt epicardial coronary artery disease. For example, with left or right ventricular hypertrophy, there is often increased wall stress and a relative imbalance between oxygen supply and demand. This could be the cause of troponin elevations in patients with and without concomitant coronary artery disease who have hypertrophic obstructive cardiomyopathy, aortic stenosis, acute pulmonary embolism, chronic pulmonary hypertension and congestive heart failure. In addition, acute myocardial stretch from increased cardiac preload can result in proteolysis of troponin and cause its release. 181 This likely is part of the mechanism for troponin elevations in patients with renal disease and those with acute congestive heart failure and perhaps pulmonary embolism.
• Pulmonary embolism: Acute right ventricular strain secondary to increases in pulmonary arterial resistance is the cause of troponin elevations in pulmonary embolism. 182 Elevations usually resolve in 40 hours or less. Pulmonary embolism can cause right ventricular infarction. 183, 184 Hypotension, hypertension and tachycardia could contribute with or without concomitant coronary artery disease. Troponin elevations are more likely to occur in patients with shock 185, 186 and clinical variables 187,188 associated with poor outcome. One might be able to measure troponin levels to determine which patients need more aggressive therapy. 187, 189 Troponin elevations in pulmonary hypertension, likely due to a pathophysiology similar to that in pulmonary embolism, also have prognostic importance. 190 • Heart failure: Elevations in cTnI and cTnT levels occur in patients with heart failure, in both the acute decompensated 191, 192 phase and the stable phase. 193, 194 Elevations are not solely due to coronary artery disease; patients with cardiomyopathy have elevations as well. These elevations have strong prognostic importance.
• Subendocardial ischemia: There is an association between increased troponin levels and left ventricular hypertrophy. 195 It is known that the subendocardium can have impaired perfusion due to increased wall stress, concomitant endothelial dysfunction and, often, increased myocardial oxygen demand. This is the mechanism for ischemia in patients with aortic stenosis, hypertrophic obstructive cardiomyopathy, and probably severe hypotension or hypertension with left ventricular hypertrophy. Catecholamines, which are released with stress and neurological insults, may also cause cardiac injury in this manner.
• Endothelial dysfunction: Recent data are clear that ischemia can be induced by endothelial abnormalities. 196 These can lead to cardiac injury and troponin release.
Key points for clinical practice
• Cardiac isoforms of troponin are specific for the heart.
• Elevated troponin levels indicate cardiac injury but do not define the mechanism.
• In patients with acute coronary ischemia and elevated troponin levels, myocardial infarction should be diagnosed; treatment should be guided by the elevated troponin levels.
• In patients who do not have acute coronary ischemia, rule out other causes of troponin elevation.
• Patients with renal failure and elevated troponin levels should be evaluated initially for acute coronary syndromes. In the absence of an acute cause of the elevation, emergent treatment may not be required. If no urgent care is needed, subsequent troponin measurement is still indicated, since troponin elevations have prognostic importance.
• Know the 99th percentile of the troponin assay used.
• Elevated troponin levels imply an adverse prognosis. In some patients (e.g., those with acute coronary syndromes) troponin elevations may be short term and long term, and in other patients (e.g., dialysis patients and those having undergone vascular surgery) they may only be long term.
• Suspect a laboratory problem if the troponin values do not change or do not match the patient's presentation. Good laboratories can help to determine whether there are analytical issues confounding the results. The first approach is to repeat the assay after additional centrifugation to be sure to eliminate fibrin interference. Kits are available to correct for the presence of heterophilic and cross-reacting antibodies. 197 
